Tirzepatide

Tirzepatide is a Dual GIP / GLP-1 Agonist supplied for laboratory research. Dual GIP and GLP-1 receptor co-agonist investigated in vitro for multi-receptor activation dynamics, insulin secretion pathway modeling, and metabolic signaling research.

Tirzepatide is the dual GIP/GLP-1 receptor agonist studied as the active compound in branded products such as Mounjaro and Zepbound. What is offered here is unformulated tirzepatide for laboratory research only, not an approved medicine.

Tirzepatide is supplied as a lyophilized (freeze-dried) powder — a dehydrated form that keeps the peptide stable during shipping and storage. In the laboratory it is reconstituted (returned to liquid form) using a solvent such as bacteriostatic water, added slowly against the side of the vial, which is then swirled gently — never shaken — until the powder fully dissolves. All handling is for in vitro research use only.

Store the lyophilized Tirzepatide powder at -20°C, protected from light and moisture, where it remains stable long-term. Once reconstituted, keep it refrigerated (2-8°C) and use it within the timeframe appropriate for your research protocol.

Every batch of Tirzepatide is produced to a purity of 99% or higher. Purity and molecular identity are verified using standard analytical methods — high-performance liquid chromatography (HPLC) to measure purity, and mass spectrometry (MS) to confirm the peptide's molecular weight.